J

Joinn Laboratories China Co Ltd
SSE:603127

Watchlist Manager
Joinn Laboratories China Co Ltd
SSE:603127
Watchlist
Price: 17.68 CNY -6.31% Market Closed
Market Cap: 11.1B CNY
Have any thoughts about
Joinn Laboratories China Co Ltd?
Write Note

Joinn Laboratories China Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Joinn Laboratories China Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
J
Joinn Laboratories China Co Ltd
SSE:603127
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Cash Paid for Dividends
-ÂĄ2.7B
CAGR 3-Years
-42%
CAGR 5-Years
-33%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Cash Paid for Dividends
-ÂĄ820.8m
CAGR 3-Years
-30%
CAGR 5-Years
-63%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Cash Paid for Dividends
-ÂĄ643.3m
CAGR 3-Years
-27%
CAGR 5-Years
-25%
CAGR 10-Years
-31%
W
WuXi XDC Cayman Inc
HKEX:2268
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Joinn Laboratories China Co Ltd
Glance View

Market Cap
11.1B CNY
Industry
Life Sciences Tools & Services

Joinn Laboratories China Co Ltd is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Beijing, Beijing and currently employs 2,140 full-time employees. The company went IPO on 2017-08-25. Joinn Laboratories China Co Ltd is a China-based company primarily engaged in the pharmacology and toxicology research of new drugs. Non-clinical research services include drug safety evaluation, pharmacokinetic research as well as pharmacological and pharmacodynamic research. Clinical trials and related services include clinical contract research organization services, phase I clinical research collaboration unit (CRU), and bioanalysis services. Experimental model business mainly includes rodents and non-human primates. The firm conducts its businesses both in the domestic market and overseas markets.

Intrinsic Value
17.6 CNY
Fairly Valued
Intrinsic Value
Price
J

See Also

Back to Top